Elevated serum IL-8 levels were found to be associated with an unfavorable prognosis in NSCLC patients treated with the PD-l antibody nivolumab, and increased IL-8 expression in tumors was negatively correlated with T cell markers and IFNγ-dependent gene signatures in the TME [48]. Here, CXCL8 is linked to non-small cell lung carcinoma.